Nurix Therapeutics NRIX Q2 2026: Roche Deal Overshadows the Miss
As seen on the 24/7 Wall St. homepage on July 9, 2026.
Nurix missed earnings and revenue badly, but the $700 million Roche upfront arriving next quarter will vault cash to $1.14 billion and fund the leap into Phase 3 trials for lead BTK degrader bexobrutideg. The quarterly flop fades against a transformative collaboration that validates targeted protein degradation as the field's future.
Continue ReadingShow less
Nurix reported a Q2 2026 loss of $0.81 per share against an estimate of roughly $0.72, a miss of about 13%. Revenue came in at $9 million, falling more than 40% short of the $15.3 million analysts had expected. The quarterly revenue trend underlines how lumpy collaboration payments can make biotech results look — Nurix posted $44 million in Q2 2025 when a prior milestone hit, making the current quarter look especially thin by comparison.
The story investors are watching is not the quarterly shortfall but the $700 million upfront payment from Roche that is set to land next quarter. That cash infusion is expected to push Nurix's total cash to $1.14 billion, which the company says is sufficient to fund the move into Phase 3 clinical trials for bexobrutideg, its lead BTK degrader. The Roche collaboration is widely seen as a validation of targeted protein degradation as an emerging therapeutic approach.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
What to watch next is the timing and structure of the Phase 3 program for bexobrutideg, and whether the Roche cash cushion allows Nurix to advance any additional pipeline assets without needing to return to the capital markets. The $1.14 billion runway materially changes the risk profile for a company that would otherwise face the typical biotech funding pressures at this stage of development.
Mentioned: NRIX